FDA grants AP status for Mylan's Saxagliptin and Metformin Hydrochloride
The FDA has granted Abbreviated Approval (AP) status for Mylan's ANDA205981 for Saxagliptin and Metformin Hydrochloride.
Asset / Drug
Drug and asset intelligence for Saxagliptin with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.